Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma - PubMed (original) (raw)
. 2009 Mar 24;123(1):31-7.
doi: 10.1016/j.imlet.2009.01.011. Epub 2009 Feb 25.
Affiliations
- PMID: 19428549
- DOI: 10.1016/j.imlet.2009.01.011
Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma
Simone Stahl et al. Immunol Lett. 2009.
Abstract
Tumors often induce tolerance in the immune system, which may contribute to the limited success of clinical vaccination against tumors. In order to develop strategies for overcoming tumor tolerance we have developed an inducible mouse model of autochthonus hepatocellular carcinoma growth, which relates more closely to the clinical situation than transplantation tumors. These so-called AST mice harbour a construct consisting of the hepatocyte-specific albumin promoter, a loxP flanked stop-cassette, and the oncogene SV40 large T antigen (Tag). By intravenous application of an adenovirus encoding Cre recombinase the stop cassette was excised, thereby inducing Tag expression and formation of hepatoma nodules in a dose-dependent fashion in about 3 months. Non-induced AST mice showed tumor tolerance, as demonstrated by the failure to reject Tag-positive transplantation tumors and the inability to mount CTL following Tag immunization. Dendritic cell-based immunization with an agonist Tag peptide was able to overcome tolerance and resulted in marked CTL activity against naturally occurring Tag epitopes. Importantly, vaccination with the agonist peptide prevented growth of the autochthonous liver tumors and significantly prolonged survival of the animals. Our findings demonstrate that agonist peptides can be used in immunization protocols for breaking of tolerance and induction of CTL that mediate effective anti-tumor responses. In addition, the inducible hepatoma model described here can be used for the design of therapeutic strategies against hepatocellular carcinoma.
Similar articles
- Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG. Neeley YC, et al. Prostate. 2008 May 15;68(7):715-27. doi: 10.1002/pros.20689. Prostate. 2008. PMID: 18302222 - In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance.
Buschow C, Charo J, Anders K, Loddenkemper C, Jukica A, Alsamah W, Perez C, Willimsky G, Blankenstein T. Buschow C, et al. J Immunol. 2010 Mar 15;184(6):2930-8. doi: 10.4049/jimmunol.0900893. Epub 2010 Feb 8. J Immunol. 2010. PMID: 20142365 - Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y, Shah S, Qiao L. Huang Y, et al. Arch Immunol Ther Exp (Warsz). 2007 Jul-Aug;55(4):205-17. doi: 10.1007/s00005-007-0029-3. Epub 2007 Jul 23. Arch Immunol Ther Exp (Warsz). 2007. PMID: 17659376 Review. - [Immune therapy against hepatocellular carcinoma using gene-modified tumor cells].
Miyagi T, Tatsumi T, Hayashi N. Miyagi T, et al. Nihon Rinsho. 2001 Oct;59 Suppl 6:688-92. Nihon Rinsho. 2001. PMID: 11762038 Review. Japanese. No abstract available.
Cited by
- Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control.
Detrés Román CR, Erwin MM, Rudloff MW, Revetta F, Murray KA, Favret NR, Roetman JJ, Roland JT, Washington MK, Philip M. Detrés Román CR, et al. J Immunother Cancer. 2024 Oct 3;12(10):e009129. doi: 10.1136/jitc-2024-009129. J Immunother Cancer. 2024. PMID: 39362791 Free PMC article. - Tumor-Reactive CD8+ T Cells Enter a TCF1+PD-1- Dysfunctional State.
Roetman JJ, Erwin MM, Rudloff MW, Favret NR, Detrés Román CR, Apostolova MKI, Murray KA, Lee TF, Lee YA, Philip M. Roetman JJ, et al. Cancer Immunol Res. 2023 Dec 1;11(12):1630-1641. doi: 10.1158/2326-6066.CIR-22-0939. Cancer Immunol Res. 2023. PMID: 37844197 Free PMC article. - Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division.
Rudloff MW, Zumbo P, Favret NR, Roetman JJ, Detrés Román CR, Erwin MM, Murray KA, Jonnakuti ST, Dündar F, Betel D, Philip M. Rudloff MW, et al. Nat Immunol. 2023 Sep;24(9):1527-1539. doi: 10.1038/s41590-023-01578-y. Epub 2023 Aug 3. Nat Immunol. 2023. PMID: 37537361 Free PMC article. - Advances in experimental animal models of hepatocellular carcinoma.
Li J, Wang X, Ren M, He S, Zhao Y. Li J, et al. Cancer Med. 2023 Jul;12(14):15261-15276. doi: 10.1002/cam4.6163. Epub 2023 May 29. Cancer Med. 2023. PMID: 37248746 Free PMC article. Review. - Intrinsic Respiratory Gating for Simultaneous Multi-Mouse μCT Imaging to Assess Liver Tumors.
Thamm M, Rosenhain S, Leonardic K, Höfter A, Kiessling F, Osl F, Pöschinger T, Gremse F. Thamm M, et al. Front Med (Lausanne). 2022 Jul 6;9:878966. doi: 10.3389/fmed.2022.878966. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35872758 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases